Health Technology Assessment: Problem, Solution, Benefit
Problem: HTA outcomes vary by country-specific evidentiary rules, benefit categories, and agency behaviour, exposing sponsors to late‑stage rejection.
Solution: A jurisdiction‑conditioned forecasting model that simulates how each HTA body will interpret clinical, economic and comparator data, delivering probability scores and key decision drivers months before submission.
Benefit: Teams can refine trial designs, sequence evidence packages and time submissions strategically, boosting approval odds and reducing re‑work costs.
Summary Overview
Healthcare systems globally are placing increasing demands on new medicines to demonstrate clinical value, economic efficiency, and regulatory alignment. Before a new medicine reaches patients, it must pass through two major decision gates:
- Health Technology Assessment (HTA): Where national agencies assess clinical trial data, cost-effectiveness, and comparative value.
- Reimbursement Negotiation: Where payers negotiate pricing, access conditions, and payment levels.
Both stages are high-stakes, unpredictable, and heavily dependent on complex data and policy environments.
This is an overview of the HTA aspects. Reimbursement are addressed in a separate overview.
The development roadmap for the HTA predictor is to produce an advanced predictive modelling platform that anticipates the likely HTA decision outcome in each country of interest designed to:
- Forecast decisions before submission.
- Simulate different clinical and economic scenarios.
- Support investment and partnership valuations.
What information will be used?
The platform will require multiple data categories, combining public, proprietary, and client-supplied inputs including:
- Clinical Trial Data such as Phase III results, survival data, response rates
- Comparator Information such as existing standard of care performance
- Economic Modelling measured in Cost per QALY, budget impact models
- Regulatory Context such as orphan designations, unmet medical need scoring
- Jurisdiction-Specific Policies including NICE thresholds, German comparator rules, US coverage frameworks, etc.
- Historical HTA Decisions to capture past agency rulings on similar drugs or therapeutic areas.
This multi-layered approach allows the system to reflect both the scientific evidence and the policy environment of each jurisdiction.
How will it work?
As a process, it proceed from Data Assembly using client or system-supplied data which will be processed into a common modelling framework.
Jurisdiction Conditioning involves capturing each country’s distinct rules. The model applies country-specific logic to weight features according to local policy.
HTA Outcome Forecast is the calculated probability of receiving a positive, conditional, or negative assessment.
In addition, users can develop Scenario Testing to adjust clinical, and economic assumptions to see how results change under different conditions. This enables ‘stress’ testing of the various constraints within the regulatory HTA process.
The Outcomes and Benefits
The system will present results through a user-friendly interface that shows:
- Predicted HTA decision (e.g. 78% chance of conditional approval in the UK).
- Confidence intervals showing forecast precision.
- Key drivers of the forecast (which features most strongly influenced the result).
- Jurisdictional comparisons across different countries.
How This Changes Decision Making
Where companies previously faced uncertainty when deciding whether to submit, they will now have an evidence-based assessment of the probability of success. The model also enables assessing the HTA process without having to submit to it, to assess readiness and likely impact on internal decision processes, which may lead to poorly formulated dossiers.
This avoids guesswork, which is often based on internal benchmarking heuristics, cross-market analogues, incomplete health economic models, and optimistic assumptions.
Rather than discovering risks late in the process, companies will be able to conduct early scenario testing before submission. This enables adjustments to development plans, strategies, or evidence packages in response to forecasted approval probabilities.
Where decision makers previously lacked clear visibility into market access risks, they will now have quantified, risk-adjusted valuations that incorporate regulatory probabilities to incorporate into valuing medicine assets.
For more information: Dr Mike Tremblay, mike_tremblay@skythunder.net